BioLife Solutions Reports Second Quarter 2026 Financial Results
BioLife Solutions (Nasdaq: BLFS) reported Q2 2026 revenue of $28.5 million, up 21% year over year, with GAAP gross margin of 64% and non-GAAP gross margin of 65%. GAAP net income was $45.1 million, including a $42.4 million non-cash tax benefit; non-GAAP adjusted EBITDA was $7.4 million. BioLife said Repligen will acquire it for about $1.5 billion, expected to close in Q4 2026.
How this was made
The 30-second read
Why it matters
Traders can update positions based on two fresh inputs: (1) Q2 2026 financial performance with improved operating income and adjusted EBITDA, and (2) a definitive acquisition agreement that will take BioLife private, shifting the stock’s risk profile toward deal completion and arbitrage dynamics.
Market read
This is a combined earnings and M&A catalyst: Q2 results show revenue growth and improved operating income, while the definitive Repligen deal introduces a clear path to take-private by Q4 2026.
What to watch
Deal completion risk (stockholder and regulatory approvals) and the probability-weighted path to Q4 2026 closing could dominate price action more than the quarter’s adjusted EBITDA trend.
Background
BioLife is a supplier of cell processing tools and services for the cell and gene therapy market, and it is now set to be acquired by Repligen.
Ticker impact
BioLife reported Q2 2026 revenue of $28.5M and disclosed a definitive deal where Repligen will acquire BioLife for about $1.5B.
Bullish bias with elevated volatility around deal approval and closing expectations; GAAP net income is boosted by a non-cash tax benefit, so traders may focus more on adjusted metrics and deal terms.
The article provides fresh, decision-relevant disclosures: Q2 financial results and a definitive acquisition agreement with stated consideration and expected Q4 2026 close. However, it does not provide BioLife guidance or detailed regulatory/financing updates that would refine the timing probability.
Market effects
Repligen’s planned acquisition of a biopreservation tools supplier may consolidate CGT manufacturing supply chains and influence competitive positioning for cell processing consumables.
Limited direct regional read-through; primary impact is on US-listed CGT tooling and services sentiment.
Potential global CGT manufacturing supply-chain consolidation signal, though the article is US-focused and does not cite international regulatory milestones.
Counterpoint
GAAP profitability is heavily influenced by a $42.4M non-cash income tax benefit, so the underlying operating momentum may be less strong than headline net income suggests.
Key entities
- public_companyBioLife Solutions, Inc.
Nasdaq-listed CGT cell processing tools and services provider reporting Q2 2026 results and announcing a definitive acquisition agreement.
- public_companyRepligen
Acquirer in a definitive agreement to purchase BioLife for about $1.5B, expected to close in Q4 2026.
